| 研究開始時の研究の概要 |
Although EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs) are commonly used to treat EGFR-mutated NSCLC, clinicians dispute the order of dosing due to different respond of patients to different EGFR-TKIs. Hence, investigate the optimal strategies for EGFR-TKI therapy is an urgent challenge. To overcome this problem, we constructed a mathematical model based on clinical observations and estimated parameters from published data. Our work recapitulated and confirmed clinical observations, and predicted the most optimized treatment options for EGFR-mutated NSCLC patients as well.
|
